AB598zimberelimabARC-25solid tumorsadvanced solid tumors
…immunological modulation, are positively correlated.Conclusions AB598 achieved complete CD39 target engagement and inhibition across …
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 601–660 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
Sulfasalazine6Tisagenlecleucel6Zonisamide6erlotinib6hydromorphone6oxcarbazepine6Botulinum Toxin A6Calcineurin inhibitors6IL-76MMAE6PD-1 inhibitors6PLEX6Saline6Tezacaftor6abiraterone6anticoagulant6antihypertensive medications6dexketoprofen6oral steroids6phenytoin6sodium bicarbonate6Baclofen6Fluoroquinolone6Itraconazole6PPI6PRAME6Rapamycin6antiseizure medications6mephedrone6n-butyl cyanoacrylate6renin-angiotensin system inhibitors6Beta blocker6Entecavir6Oral corticosteroids6Valganciclovir6anti-seizure medications6cabotegravir/rilpivirine6citalopram6dextran sulfate sodium6penicillins6stimulants6teicoplanin6HRT5Treprostinil5Glimepiride5Orlistat5NKTR-2555Emicizumab5Efgartigimod5Sarilumab5Etrasimod5CAB-LA5D-Dimer5GDF-155TMZ5TAF5Darolutamide5ESPB5Marijuana53TC5
Articles mentioning drugs
10,506 articles · page 121 of 876avelumabutomilumabPF-04518600anti-OX40anti-4-1BBOX40The University of Texas MD Anderson Cancer CenterPfizersolid tumorscolorectal and pancreatic cancers
…pre-treatment longitudinal changes following the combination of avelumab with utomilumab (a 4-1BB agonist) (arm A), PF-04518600 (an OX40…
nivolumabpepinemabipilimumabPepinemab-containingavelumabmetastatic melanomaEmory University
…s, followed by curative-intent surgery and one year of adjuvant nivolumab. Primary study endpoints included multiomic profiling of surgic…
FT836mAbsolid tumorsprostatecervical cancers
…ograft models of prostate, ovarian, lung, and cervical cancers, FT836 achieved tumor growth inhibition rates of 94.5% ± 5.0% ( figure…
Delta-24-RGDOX-IL15Delta-24-RGOX-IL15delta-24-RGDOXDelta-24-RGDAdvanced solid tumorsrecurrent glioblastoma
…ight the potent immunostimulatory and therapeutic properties of Delta-24-RGDOX-IL15 and support its potential to synergize with CAR T cell therapy …
Cy/FlucyclophosphamidefludarabineIL-12 GEMysOsteosarcomarhabdomyosarcomaNational Institutes of HealthIL-12 GEMy therapy
…ated by an immunosuppressive myeloid infiltrate. Treatment with Cy/Flu depleted most circulating immune cells and TAMs. Cy/Flu plus IL…
DenosumabCapmatinibAtezolizumabCarboplatinAtezolezumabPemetrexedPemetexedCampatinibnon-small cell lung cancerNSCLC
…palliative ChT-IO with Atezolezumab + Pemetexed + Carboplatin + Denosumab followed by Maintenance Chemo IO with Pemetrexed + Atezolizumab…
AkkPD-1 inhibitorsWest China Hospital of Sichuan UniversityInstitutional Review BoardCRCimmunotherapyClinicalTrials.gov
…and systemic immune profile dynamics.Results In animal studies, Akk suppressed tumor-associated macrophages (TAMs) efferocytosis. T…
ipilimumabnivolumabplatinum doublet chemotherapyNSCLCMD Anderson Cancer Centernon-small-cell lung cancernon-small cell lung cancerplatinum doublet therapyplatinum-doublet chemotherapy
…histology-specific platinum doublet chemotherapy, combined with ipilimumab (1 mg/kg every 6 weeks) and nivolumab (360 mg every 3 weeks), f…
pembrolizumabnivolumabipilimumabstage III cutaneous melanomastage III-IV cutaneous melanomaadjuvant therapy
…nter. Patients received either nivolumab + ipilimumab (n=21) or pembrolizumab monotherapy (n=31). Radiological responses were assessed using …
dexamethasoneCMD03anakinraB7-H3B7-H3-targetingChulalongkorn UniversityDiffuse intrinsic pontine glioma (DIPG)DIPGCancer Immunol Immunother
…, which resolved within 24 to 72 hours following treatment with dexamethasone and anakinra. CMD03 CAR T cells were monitored weekly in the ce…
IL-12IL-15IL-18pembrolizumabNivolumabfludarabineavelumabgemcitabinebevacizumabAtezolizumab+7 more
…d.aaf2341Leong JW, Chase JM, Romee R, et al. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity I…